The US affiliate of specialty pharmaceutical company Indivior has launched an authorised generic version of Suboxone (buprenorphine and naloxone) sublingual film, a prescription medicine developed to treat of opioid dependence, in the United States, it was reported yesterday.
Sandoz will market the authorised generic version of Suboxone on behalf of Indivior in the US.
Indivior stated that its decision is based on the market impact expected from the anticipated at risk launch of a generic buprenorphine film product in the US by Dr Reddy's Laboratories and Alvogen Pine Brook.
On 19 February, the US Supreme Court rejected Indivior's motion to stay issuance of the mandate vacating the preliminary injunction (PI) granted against Dr Reddy's. Later, the US District Court for the District of New Jersey passed orders to dissolve the temporary restraining order against Alvogen and confirming the PI against Dr Reddy's had been vacated.
The court decision allows Dr Reddy's and Alvogen to sell or import their generic buprenorphine/naloxone sublingual film products.
Annexin Pharmaceuticals receives proposed INN vanexin for ANXV
Henlius and Sandoz expand biosimilars collaboration
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent